Browse the evidence

Mean percentage weight change at 1 year was -5.1% with semaglutide compared to -2.2% with liraglutide (P < .001).

Semaglutide may be more effective than liraglutide for weight loss in clinical practice.

Weight change at 6 months was -4.31% for the standardized group and -3.26% for the personalized group.

Both diet approaches resulted in weight loss, but the standardized low-fat diet was more effective.

Tirzepatide facilitated an average 18.5% weight loss (>46 pounds) in overweight and obese patients with type 1 diabetes at 1 year.

Practitioners may consider tirzepatide as an effective option for weight management in this patient population.

Adequate dietary sources or supplements of specific nutrients are necessary for vegan diets.

Health professionals should ensure that vegan patients receive adequate nutrients through diet or supplements.

The Mediterranean Diet may be of greater interest for the management of T2DM.

Consider recommending the Mediterranean Diet as a potential strategy for managing T2DM.

The recommended dietary prescription for the Mediterranean Diet includes 40-50% carbohydrates, 15-25% proteins, and 25-35% fats.

Use these macronutrient guidelines when advising patients on the Mediterranean Diet for T2DM management.

The ACSM supports the inclusion of physical activity in medical treatments for excess weight and adiposity.

Practitioners should incorporate physical activity into treatment plans for patients with excess weight.

For weight loss and prevention of weight gain, physical activity should be progressed to at least 150 min·wk-1 of moderate-intensity.

Encourage clients to engage in at least 150 minutes of moderate-intensity physical activity weekly for effective weight management.

The low-carbohydrate diet intervention group had a significant reduction in body weight of -5.9 kg.

A low-carbohydrate diet may contribute to significant weight loss in individuals with prediabetes or untreated diabetes.

Semaglutide reduced body weight more in women than in men, with a mean difference of -9.6% in women and -7.2% in men.

Practitioners should note that women may experience greater weight loss with semaglutide treatment.

At week 72, mean absolute T2D predicted risk score reductions were significantly greater in tirzepatide groups (5 mg, 12.4%; 10 mg, 14.4%; 15 mg, 14.7%) versus placebo (0.7%).

The specific dose of tirzepatide can be tailored to achieve greater reductions in diabetes risk.

For participants with and without prediabetes, risk reductions were significantly greater in tirzepatide groups versus placebo.

Tirzepatide may be beneficial for a broader range of patients, including those with prediabetes.

INV-202 produced a significant mean weight loss of 3.5 kg (3.3% compared with placebo participants who gained a mean 0.6 kg [0.5%]).

INV-202 may be an effective treatment for weight loss in individuals with metabolic syndrome.

Metabolic bariatric surgery (MBS) was associated with greater total weight loss (mean 28.3%) compared to GLP-1 receptor agonists (mean 10.3%) in patients with class II and III obesity.

MBS may be a more effective option for significant weight loss in patients with higher obesity classes.

A Mediterranean diet should serve as a basis that can be restructured into other kinds of diets for NAFLD patients.

Practitioners should consider using a Mediterranean diet as a flexible foundation for dietary recommendations for NAFLD patients.

Dietary composition is important for long-term health outcomes in NAFLD patients.

Practitioners should prioritize healthy dietary compositions to ensure long-term safety and efficacy for NAFLD patients.

The intervention group achieved significantly higher protein intake at 26–28 weeks and 36–38 weeks gestation.

Practitioners should focus on increasing protein intake in pregnant women through structured dietary interventions.

The treatment with GLP-1 RA resulted in a reduction in the risk of any cardiovascular event with a relative risk of 0.81.

The relative risk indicates a significant benefit of GLP-1 RA in reducing cardiovascular events.

For diabetes remission in newly diagnosed diabetes (NDD), the recommended macronutrient composition is 49-54% carbohydrates, 19-20% protein, and 21-26% fat.

Practitioners should consider these macronutrient ratios when advising patients with newly diagnosed diabetes.

For prediabetes (PD) remission to normal glucose tolerance (NGT), the recommended macronutrient composition is 50-56% carbohydrates, 18-20% protein, and 21-27% fat.

Practitioners should consider these macronutrient ratios when advising patients with prediabetes.

To prevent progression to type 2 diabetes (T2D) in prediabetes and normal glucose tolerance groups, the recommended macronutrient compositions are 54-57% carbohydrates, 16-20% protein, and 20-24% fat for prediabetes, and 56-60% carbohydrates, 14-17% protein, and 20-24% fat for normal glucose tolerance.

Practitioners should consider these macronutrient ratios when advising patients at risk of developing type 2 diabetes.

Replacing 5% energy from animal fat with 5% energy from plant fat is associated with a 4% to 24% reduction in overall mortality and a 5% to 30% reduction in CVD mortality.

Encouraging dietary fat substitution can significantly reduce mortality risks.

Participants treated with SAR425899 lost more weight, fat mass, and fat free mass compared to those on placebo (p < 0.05).

SAR425899 may enhance weight loss and body composition improvements.

Plant-based dietary patterns rich in minimally processed foods, vegetables, and fruits reduce CVD risk.

Health professionals should recommend plant-based diets rich in whole foods to reduce CVD risk.